|MDACC Study No:||2006-0066 (clinicaltrials.gov NCT No: NCT00439556)|
|Title:||Bortezomib (VelcadeŽ) and Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with Lymphoid Malignancies|
|Principal Investigator:||Issa F. Khouri|
|Treatment Agent:||Carmustine; Cytarabine; Etoposide; Melphalan; Rituximab; Velcade|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of Velcade (bortezomib) that can be given with BEAM (carmustine, etoposide,
cytarabine and melphalan) and rituximab in patients with lymphoma who receive a
stem cell transplant.